VTRS

시간 외 거래: 8.98 0.08 +0.90%

비아트리스 (VTRS)

개요 뉴스 가격 이력 옵션 체인 Financials 토론 예측 주식 분할 배당 이력

Relative Volume:

비아트리스 Stock (VTRS) Company Profile

Healthcare (1161)

(724) 514-1465

1000 MYLAN BOULEVARD, CANONSBURG

최신 SEC 제출 서류

VTRS's Discussions on Twitter

VTRS을(를) 다른 주식과 비교

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
VTRS Viatris Inc	8.90	10.73B	14.33B	-3.79B	1.84B	-3.17
ZTS Zoetis Inc	147.37	69.30B	9.29B	2.52B	2.28B	5.57
TAK Takeda Pharmaceutical Co Adr	14.44	47.50B	30.08B	710.16M	4.45B	0.2182
HLN Haleon Plc Adr	9.53	44.47B	14.35B	1.85B	0	0.4023
TEVA Teva Pharmaceutical Industries Ltd Adr	16.31	18.83B	16.54B	-1.64B	749.00M	-1.45
UTHR United Therapeutics Corp	293.12	13.43B	2.99B	1.21B	1.13B	25.06

비아트리스 Stock (VTRS) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2025-06-06	개시	Goldman	Neutral
2024-07-19	재개	Jefferies	Buy
2023-10-23	다운그레이드	BofA Securities	Neutral → Underperform
2023-06-23	다운그레이드	Barclays	Equal Weight → Underweight
2023-04-24	다운그레이드	Barclays	Overweight → Equal Weight
2023-02-17	다운그레이드	BMO Capital Markets	Outperform → Market Perform
2023-01-27	업그레이드	Jefferies	Hold → Buy
2022-11-10	업그레이드	UBS	Sell → Neutral
2022-11-08	업그레이드	Piper Sandler	Underweight → Neutral
2022-10-21	재개	Jefferies	Hold
2022-06-14	개시	UBS	Sell
2022-05-10	다운그레이드	Piper Sandler	Neutral → Underweight
2022-03-01	다운그레이드	BofA Securities	Buy → Neutral
2022-03-01	다운그레이드	Raymond James	Outperform → Mkt Perform
2021-06-15	개시	Citigroup	Neutral
2021-04-07	재개	RBC Capital Mkts	Outperform
2021-03-08	다운그레이드	Goldman	Buy → Neutral
2021-03-02	다운그레이드	JP Morgan	Overweight → Neutral
2021-02-26	다운그레이드	Wolfe Research	Outperform → Peer Perform
2021-01-05	개시	Argus	Hold
2020-12-14	개시	Bernstein	Mkt Perform

비아트리스 주식(VTRS)의 최신 뉴스

비아트리스 (VTRS) 재무 분석

비아트리스 (VTRS)

비아트리스 Stock (VTRS) Company Profile

VTRS을(를) 다른 주식과 비교

비아트리스 Stock (VTRS) Upgrades & Downgrades

비아트리스 주식(VTRS)의 최신 뉴스

Agree To Buy Viatris At $5, Earn 3% Using Options - Nasdaq

VTRS Down on Late-Stage Study Failure of Eye Disease Drug - TradingView

Viatris’ blepharitis ointment fails Phase III trial - Yahoo Finance

Viatris Phase III MR-139 trial in blepharitis misses goal - The Pharma Letter

What drives Viatris Inc. stock priceConsistently high yield - PrintWeekIndia

Viatris Inc. Stock Analysis and ForecastHigh-profit stock alerts - jammulinksnews.com

Is Viatris Inc. a good long term investmentGame-changing capital returns - PrintWeekIndia

What analysts say about Viatris Inc. stockPowerful profit generation - jammulinksnews.com

Viatris' Setback in Blepharitis Trial: A Harbinger or a Hurdle for Ophthalmic Innovation? - AInvest

Trend Tracker for (VTRS) - news.stocktradersdaily.com

Viatris Inc. Stock Forecasts: Trial Miss Pressures Recovery of Core Business - AInvest

Viatris Stock Slides After Phase 3 Blepharitis Drug Trial Misses Key Target - TradingView

Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review - Benzinga

Why Viatris (VTRS) Stock Is Falling Today - Yahoo Finance

Viatris stock unchanged as Goldman maintains Neutral rating on trial miss - Investing.com

Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire

Viatris Stock Tumbles as Eyelid Inflammation Treatment Misses Target - Barron's

Viatris' Resilience in Ophthalmology: Navigating Setbacks and Strategic Growth - AInvest

Why Is Viatris Stock Falling In Pre-market? - Nasdaq

Viatris stock down on late-stage trial setback (VTRS:NASDAQ) - Seeking Alpha

Viatris eye ointment fails late-stage study for eye condition, shares fall - TradingView

Viatris stock falls after Phase 3 blepharitis study misses endpoint - Investing.com

Viatris blepharitis treatment fails to meet primary endpoint in trial - Investing.com Australia

Viatris eye therapy fails to meet late-stage trial goal - TradingView

Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis - PR Newswire

Viatris (VTRS) Announces Positive Top-line Results from VEGA-3 - MSN

Hypopituitarism Treatment Market Expansion Supported - openPR.com

Viatris: A Contrarian Bet with Minimal Downside Risk - AInvest

Viatris: A Contrarian Bet With Virtually No Downside (NASDAQ:VTRS) - Seeking Alpha

Q1 Earnings Highs And Lows: Viatris (NASDAQ:VTRS) Vs The Rest Of The Generic Pharmaceuticals Stocks - Yahoo Finance

Goldman Sachs Reiterates a Hold Rating on Viatris (VTRS) With a $10 PT - MSN

Viatris Gains China Approval for COPD Drug Yupelri, Triggers $7.5M Payment to Theravance BioPharma - Insider Monkey

Viatris' Canadian Workplace Excellence Fuels Long-Term Resilience in Pharma's Turbulent Landscape - AInvest

Viatris Certified as a Great Place to Work® in Canada - Yahoo Finance

What makes Viatris Inc. stock price move sharplyFree Premium Stock Market Reports - beatles.ru

Non-Opioid Patch Market CAGR 6.6 percent overview and leading - openPR.com

Viatris Inc. (VTRS) Stock Analysis: Evaluating a 24.86% Potential Upside Amidst Financial Headwinds - DirectorsTalk Interviews

J&J wins appeals court ruling against Teva and Viatris in patent dispute over neuro drug - Seeking Alpha

When (VTRS) Moves Investors should Listen - news.stocktradersdaily.com

Viatris sees positive top-line phase 3 results for night driving impairment asset - MSN

J&J defeats generic drugmakers in US appeal over schizophrenia treatment - TradingView

J&J Invega Sustenna Patent Beats Teva, Viatris Appeals (Correct) - Bloomberg Law News

Viatris Inc. (VTRS) Stock Analysis: Exploring a 22.18% Potential Upside Amidst Strong Free Cash Flow and High Dividend Yield - DirectorsTalk Interviews

Theravance higher as China approves Viatris-partnered COPD therapy - MSN

Viatris says second phase 3 trial of blurred vision drug meets goal - Seeking Alpha

Viatris Reports Positive Data From Presbyopia Study - Nasdaq

Is Viatris Stock Underperforming the S&P 500? - MSN

Is Viatris Stock Underperforming The S&P 500? - Barchart.com

Same Company, Different Operating System: Carlos’ Neurodiverse Journey - Viatris

Andrew Smith Reports 2.90% Stake In Smarter Web Company As At June 13 Vs Prior Stake Of 10.39% - MarketScreener

비아트리스 (VTRS) 재무 분석

매출

순이익

현금흐름

주당 순 이익

VTRS과 유사한 종목